By revealing the protein activity in individual cells, single-cell proteomics offers powerful insights into cancer cells, both during disease and in response to therapy. Single-cell and highly multiplexed bulk proteomics have been used to perform immune profiling and assess polyfunctionality, which is defined as the ability of an individual cell to simultaneously produce multiple cytokines.
Polyfunctionality has been associated with long-term immune responses and outcomes for cancer therapies, including chimeric antigen receptor T-cell (CAR-T) therapy and adoptive cell transfer (ACT).
Download this eBook to learn about recent research on the role of single-cell proteomics and polyfunctionality in immune profiling for cancer.
CAR-T therapy uses T-cells with engineered receptors to bind cancer-associated antigens displayed on cell membranes, thereby enabling the immune system to recognize cancer cells. By leveraging the immune system to target and perform cytotoxic killing of these cancerous cells, CAR-T therapy allows for localized, persistent, and efficient targeting of the tumor. However, for some individuals, antigen loss after CAR-T therapy results in treatment failure.
Single-cell proteomics can help identify predictive biomarkers for the prognosis of these treatments as well as potential therapeutic targets, leading to the development of more effective CAR-T therapies for patients.
Watch this webinar to learn more about recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T product quality.
During disease and in response to treatment, the proteomic profiles of cancer cells are altered. Widespread changes to the proteome of a cell are often downstream of mutations in regulatory genes. In fact, the cell cycle regulator p53 is one of the most frequently mutated genes in cancer. Single-cell proteomics can be leveraged to understand exactly how p53 affects pro-tumorigenic and inflammatory molecules in the cancer environment.